Cytek Biosciences, Inc. Jury Verdict in Patent Trial — $56.11M Award

What Happened

• On August 21, 2026 (reported in an 8-K filed Aug 24, 2026), a jury in the U.S. District Court for the District of Delaware returned a verdict in the patent infringement case brought by Beckman Coulter, Inc. The jury found Cytek not liable on three of four asserted patent claims (finding noninfringement and invalidity for those three). For the remaining claim, the jury found no literal infringement but found infringement under the "doctrine of equivalents" (a legal theory that can find infringement even if the accused product does not literally match patent wording). The jury awarded past damages of $20.0 million in lost profits plus $36.11 million in royalties, totaling $56.11 million. Cytek says it intends to file post‑verdict motions challenging the doctrine of equivalents finding and the damages award and may pursue an appeal.

Key Details

• Case & filing: Jury verdict announced Aug 21, 2026; Form 8‑K furnished Aug 24, 2026 (Reg FD disclosure included, press release is Exhibit 99.1).
• Claim outcomes: 3 of 4 asserted claims found noninfringed/invalid; 1 claim found infringed under doctrine of equivalents (no literal infringement).
• Damages awarded: $20.0 million (lost profits) + $36.11 million (royalties) = $56.11 million (past damages).
• Next steps: Company plans post‑verdict motions and may appeal to the U.S. Court of Appeals for the Federal Circuit.

Why It Matters

• The verdict creates a near‑term potential cash exposure of $56.11 million, but the company prevailed on most asserted claims, which limits the scope of the loss.
• Cytek has announced it will challenge the finding and award, so the final financial and operational impact is uncertain — additional court rulings, appeals, or settlements could change outcomes, and the company flagged the possibility of further costs, injunctive relief, or ongoing royalties.
• Investors should note the litigation outcome is mixed: favorable on multiple claims, but with a significant damages award and ongoing legal risk until post‑trial motions and any appeals are resolved.